ErlySign, an Indian healthtech startup, has received Breakthrough Device Designation from the US FDA for its non-invasive, saliva-based oral cancer screening test. The rapid, point-of-care solution detects early-stage oral cancer with high accuracy using a simple saliva sample, addressing a critical need for affordable, accessible screening in high-risk populations worldwide.
Glimpse:
The ErlySign test uses proprietary biomarkers and AI-driven analysis to identify oral cancer indicators from a small saliva sample in minutes. FDA Breakthrough status accelerates development, assessment, and market access by offering priority review, frequent FDA interaction, and rolling submission options. This milestone positions ErlySign to bring a low-cost, non-invasive alternative to painful biopsies and visual exams, potentially transforming early detection in India and globally.
ErlySign, a Bengaluru-based medtech startup specializing in non-invasive cancer diagnostics, has been granted Breakthrough Device Designation by the US Food and Drug Administration (FDA) for its innovative saliva-based oral cancer screening test. The designation, awarded in early 2026, recognizes the test’s potential to provide more effective diagnosis or treatment of life-threatening diseases with unmet medical needs.
Oral cancer remains one of the most common cancers in India, with high incidence linked to tobacco use, betel quid chewing, and HPV. Late-stage diagnosis contributes to poor survival rates. Current screening relies heavily on visual inspection and invasive biopsies methods that are subjective, resource-intensive, and often inaccessible in rural areas.
ErlySign’s test requires only a simple saliva rinse. The sample is analyzed using patented biomarker detection combined with AI algorithms to deliver a rapid risk assessment for oral cancer. Early validation studies have shown promising sensitivity and specificity for detecting precancerous and early cancerous lesions, offering a scalable, patient-friendly alternative to traditional methods.
FDA Breakthrough Device status provides several advantages: Expedited development and review process Priority access to FDA experts for guidance Rolling submission of data rather than waiting for a complete package Potential for faster market authorization in the US
The designation validates ErlySign’s technology and opens doors for accelerated clinical trials, strategic partnerships, and global commercialization. The company plans to expand validation in India and other high-burden regions while pursuing full FDA clearance and CDSCO approval.
This achievement highlights India’s rising prominence in innovative, affordable cancer diagnostics and brings hope for earlier intervention in one of the country’s most prevalent yet preventable cancers.
“A simple saliva test could save countless lives by catching oral cancer before it becomes deadly. FDA Breakthrough status is a major step toward making that a reality.”
By
HB Team
